prikaz prve stranice dokumenta The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis
  Download
PDF 453.47 KB
Scientific paper - Case study
The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis
European Archives of Oto-Rhino-Laryngology, 273 (2016), 9; 2305-2317. https://doi.org/10.1007/s00405-015-3710-x
Bišof, Vesna; Zajc Petranović, Matea; Rakušić, Zoran; Samardžić, Kristina Ruža; Juretić, Antonio

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Bišof, V., Zajc Petranović, M., Rakušić, Z., Samardžić, K. R. & Juretić, A. (2016). The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis. European Archives of Oto-Rhino-Laryngology, 273. (9), 2305-2317. doi: 10.1007/s00405-015-3710-x

Bišof, Vesna, et al. "The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis." European Archives of Oto-Rhino-Laryngology, vol. 273, no. 9, 2016, pp. 2305-2317. https://doi.org/10.1007/s00405-015-3710-x

Bišof, Vesna, Matea Zajc Petranović, Zoran Rakušić, Kristina Ruža Samardžić and Antonio Juretić. "The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis." European Archives of Oto-Rhino-Laryngology 273, no. 9 (2016): 2305-2317. https://doi.org/10.1007/s00405-015-3710-x

Bišof, V., et al. (2016) 'The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis', European Archives of Oto-Rhino-Laryngology, 273(9), pp. 2305-2317. doi: 10.1007/s00405-015-3710-x

Bišof V, Zajc Petranović M, Rakušić Z, Samardžić KR, Juretić A. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis. European Archives of Oto-Rhino-Laryngology [Internet]. 2016 September [cited 2024 May 14];273(9):2305-2317. doi: 10.1007/s00405-015-3710-x

V. Bišof, M. Zajc Petranović, Z. Rakušić, K. R. Samardžić and A. Juretić, "The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis", European Archives of Oto-Rhino-Laryngology, vol. 273, no. 9, pp. 2305-2317, September 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:486557. [Accessed: 14 May 2024]

Metadata
Title (english)The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis
AuthorVesna Bišof
AuthorMatea Zajc Petranović
AuthorZoran Rakušić
AuthorKristina Ruža Samardžić
AuthorAntonio Juretić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a prognostic and predictive factor for platinum-based treatment in head and neck squamous cell carcinoma (HNSCC) but with inconsistent results. We performed the present meta-analysis to better elucidate this issue in advanced HNSCC. A literature search was conducted using the PubMed and Web of Science databases. The inclusion criteria were head and neck cancer patients with platinum-based treatment and evaluation of the correlation between ERCC1 expression and clinical outcomes [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), both unadjusted and adjusted estimates]. In high vs. low pooled analyses, high ERCC1 expression was associated with unfavorable OS [hazard ratio (HR) = 1.95, 95 % confidence interval (CI) 1.18-3.21, p = 0.009], PFS (HR = 2.39, 95 % CI 1.74-3.28, p = 0.000) and ORR (odds ratio = 0.48, 95 % CI 0.23-0.98, p = 0.044). In the subgroup analysis of adjusted OS estimates, ERCC1 was a predictor of shorter survival in Asians (HR = 3.13, 95 % CI 2.09-4.70, p = 0.000) and Caucasians (HR = 2.02, 95 % CI 1.32-3.07, p = 0.001) but of longer survival in South Americans (HR = 0.17, 95 % CI 0.07-0.40, p = 0.000). Immunohistochemistry proved to be of predictive value irrespective of used antibody (p = 0.009). In the stratified analysis according to the tumor site, ERCC1 expression was associated with OS in nasopharyngeal cancer (HR = 2.72, 95 % CI 1.79-4.13, p = 0.000). ERCC1 has a potential to become predictive and prognostic factor enabling treatment tailoring in HNSCC patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleEuropean Archives of Oto-Rhino-Laryngology
Numberingvol. 273, no. 9, pp. 2305-2317
p-ISSN0937-4477
DOIhttps://doi.org/10.1007/s00405-015-3710-x
URN:NBNurn:nbn:hr:105:486557
Publication2016-09
Document URLhttps://doi.org/10.1007/s00405-015-3710-x
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:53:21